NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Association of CCR5-D32 mutation with Hepatitis C seroprevalence and incidence in a large cohort of women.

Madhava V, Feldman J, Philpott S, Augenbraum M, Burger H, Cohen M, Young M, Anastos K; International Conference on AIDS.

Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. TuPeA4365.

Montefiore Medical Center, New York, United States

BACKGROUND: Homozygous mutation (D32, D32) of CCR5 co-receptor gene is known to prevent HIV infection and heterozygosity (D32, Wild Type-WT) is partially protective. There is conflicting evidence on the association of Hepatitis C (HCV) infection and mutation of the CCR5 co-receptor. METHODS: Among 2518 participants in the Women's Interagency HIV Study, with known CCR5 genotype, HIV status, and HCV serostatus, prevalence of D32 mutation was compared among groups defined by HCV and HIV serostatus. RESULTS: Mean age=39.4. 55% were African American, 25% Latinas and 17% Caucasians. Only one HIV -, HCV- Caucasian woman had the double mutation (D32, D32). CCR5 heterozygosity (D32, WT) was present in 4.6% of women with HCV infection. The odds ratio (OR) in comparing women with and without HCV infection was 0.7 (95% Confidence Interval (CI) 0.49-1.00), p=0.05. Cohort distribution and CCR5 D32 prevalence: [table: see text] CCR5 heterozygosity in HCV infected compared to HCV uninfected women was OR 0.62 (95% CI 0.39-0.95) and OR 1.24 (95% CI 0.58-2.53), among HIV+ and HIV- women, respectively. The incidence data on HCV indicate that among 4,530 person years (py) of follow up in women without a mutation (WT/WT), 25 cases (0.55/100py) developed. For heterozygotes, no new HCV cases occurred with 280 py of follow up. We would have expected about 1.5 cases. CONCLUSIONS: In this large cohort of HIV positive and negative women, representative of the HIV infected female population in the US, we found decreased frequency of CCR5 D32 heterozygous genotype among HCV infected women compared to HCV uninfected women, particularly among those with HIV co-infection, suggesting that CCR5 heterozygotic mutation may confer partial protection against HCV infection.

Publication Types:
  • Meeting Abstracts
Keywords:
  • AIDS Vaccines
  • Acquired Immunodeficiency Syndrome
  • Female
  • Genotype
  • HIV Infections
  • HIV Seropositivity
  • Hepacivirus
  • Hepatitis C
  • Hepatitis C Antibodies
  • Heterozygote
  • Humans
  • Incidence
  • Mutation
  • Prevalence
  • Receptors, CCR5
  • Seroepidemiologic Studies
  • genetics
Other ID:
  • GWAIDS0020214
UI: 102259251

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov